Press Releases 2024

The Fraunhofer Institute for Biomedical Engineering IBMT signed letters of intent for future cooperation with Korea Conformity Laboratories KCL and KIST Europe on April 16, 2024 in Sulzbach, Saarland.

Memory impairment, orientation problems and speech difficulties can be signs of the onset of Alzheimer's dementia. This disease is not yet curable, but its progression can be slowed down with medication and supportive measures. The EU project "CombiDiag" is a doctoral network funded under the Marie Skłodowska-Curie actions of Horizon Europe, aiming to train ten doctoral students in the field of multimodal peripheral markers and their combinatorial use for the diagnosis of early-stage Alzheimer's disease (AD). A combinatorial diagnostic protocol may serve as a crucial tool for accurate screening and identification of patients in the earliest stages of AD, before irreversible damage and associated symptoms occur. The aim of the "CombiDiag" project is to develop disease-modifying measures and treatments. The Fraunhofer IBMT is contributing its expertise in the development of printed electrodes for biosensor applications and microfluidics to the project.

The EU project "ArtPlac" is a preclinical research project to develop an innovative technology for medical treatments in neonatal intensive care. The project involves an international research team of physicians and engineers, supported by an organization that represents the interests of premature and newborn babies and their families. The Fraunhofer Institute for Biomedical Engineering IBMT is contributing its expertise in the development of microfluidic systems and sensor development and integration to the project. The aim of the project is to develop a combined lung and kidney support device for connection to the umbilical vessels. The device enables a less invasive approach than the therapies currently in use. This new approach should reduce the risk and medical burden for the newborn.